Results 61 to 70 of about 18,647 (241)

A case report of bullous pemphigoid following secukinumab therapy for a patient with psoriasis

Journal of Dermatological Treatment
Aim: Bullous pemphigoid induced by secukinumab in treatment of psoriasis is rare.Methods: We report a 49-year-old man with psoriasis who developed bullous pemphigoid during treatment with secukinumab.Results: Scattered tense vesicles with itching ...
Guanghan Wang, Xiaojing Hu, Shixin Han, Meijuan Zhou   +3 more
doaj   +1 more source

Structured Diagnostic Approach and Risk Assessment in Mucous Membrane Pemphigoid with Oesophageal Involvement

Acta Dermato-Venereologica, 2018
Oesophageal involvement in mucous membrane pemphigoid is considered rare, but it may be underdiagnosed. To assess the incidence of oesophageal involvement in a group of patients with newly diagnosed mucous membrane pemphigoid we retrospectively analysed ...
Sandrine Benoit, Michael Scheurlen, Matthias Goebeler, Johanna Stoevesandt   +3 more
doaj   +1 more source

Proteases in Pemphigoid Diseases

Frontiers in Immunology, 2019
Pemphigoid diseases are a subgroup of autoimmune skin diseases characterized by widespread tense blisters. Standard of care typically involves immunosuppressive treatments, which may be insufficient and are often associated with significant adverse ...
Sho Hiroyasu, Sho Hiroyasu, Sho Hiroyasu, Christopher T. Turner, Christopher T. Turner, Christopher T. Turner, Katlyn C. Richardson, Katlyn C. Richardson, Katlyn C. Richardson, David J. Granville, David J. Granville, David J. Granville   +11 more
doaj   +1 more source

Alterations of Total Serum Immunoglobulin Concentrations in Pemphigus and Pemphigoid: Selected IgG2 Deficiency in Bullous Pemphigoid

Frontiers in Medicine, 2020
Pemphigus and pemphigoid diseases are organ-specific autoimmune diseases of the skin and/or mucous membranes, which are caused by autoantibodies targeting structural proteins of the skin.
Stanislav Khil'chenko, Stanislav Khil'chenko, Katharina Boch, Katharina Boch, Nina van Beek, Nina van Beek, Artem Vorobyev, Artem Vorobyev, Detlef Zillikens, Detlef Zillikens, Enno Schmidt, Enno Schmidt, Enno Schmidt, Ralf J. Ludwig, Ralf J. Ludwig   +14 more
doaj   +1 more source

Clinical Relevance of Autoantibodies in Patients with Autoimmune Bullous Dermatosis

Clinical and Developmental Immunology, 2012
The authors present their experience related to the diagnosis, treatment, and followup of 431 patients with bullous pemphigoid, 14 patients with juvenile bullous pemphigoid, and 273 patients with pemphigus.
Lilla Mihályi, Mária Kiss, Attila Dobozy, Lajos Kemény, Sándor Husz   +4 more
doaj   +1 more source

Assessment of the Characteristics and Associated Factors of Infectious Complications in Bullous Pemphigoid

Frontiers in Immunology, 2020
Objectives: The clinical outcome of bullous pemphigoid appears worse in patients with infectious complications, and assessment of the prevalence and risk factors of infectious complications could be necessary to plan preventative strategies and to ...
Jia Chen, Xuming Mao, Wenling Zhao, Wenling Zhao, Bingjie Zhang, Xinyi Chen, Chenyang Yu, Zehui Zheng, Hongzhong Jin, Li Li   +9 more
doaj   +1 more source

Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases

Frontiers in Immunology, 2022
Chronic blistering at the skin and/or mucous membranes, accompanied by a varying degree of inflammation, is the clinical hallmark of pemphigoid diseases that impose a major medical burden.
Saeedeh Ghorbanalipoor, Shirin Emtenani, Melissa Parker, Mayumi Kamaguchi, Colin Osterloh, Manuela Pigors, Natalie Gross, Stanislav Khil’chenko, Anika Kasprick, Sabrina Patzelt, Diana Wortmann, Ibrahim O. Ibrahim, Kentaro Izumi, Stephanie Goletz, Katharina Boch, Kathrin Kalies, Katja Bieber, Paul Smith, Enno Schmidt, Ralf J. Ludwig   +19 more
doaj   +1 more source

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

Allergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz, Salvador Iborra, Carlos Blanco, Ruperto González‐Pérez, Emilio Nuñez‐Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie‐Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J. Torres, Mohamed Shamji, Mübeccel Akdis, Kari C. Nadeau, Ismail Ogulur, Cezmi A. Akdis   +22 more
wiley   +1 more source

New-onset bullous pemphigoid following the fifth dose of the COVID-19 vaccine Pfizer-BioNTech: A case report

SAGE Open Medical Case Reports
Bullous pemphigoid is recognized as the most prevalent autoimmune blistering skin disease. This report presents a case of a 54-year-old male in Canada who developed new-onset bullous pemphigoid 4 weeks after receiving his fifth COVID-19 vaccine booster ...
Eman Badawod
doaj   +1 more source

Emerging Paediatric Uses of Dupilumab Beyond Approvals

Clinical &Experimental Allergy, EarlyView.
Dupilumab, through IL‐4Rα blockade, shows promising efficacy beyond approved indications in paediatric diseases driven by T2 inflammation. Emerging evidence—mainly from small studies—supports improvements in disease severity and quality of life, highlighting its potential as a targeted, steroid‐sparing therapy while underscoring the need for ...
Simone Foti Randazzese, Anna Calamita, Diletta D'Angelo, Alessia Marseglia, Esther Mesa Lombardero, Sara Pedersoli, Micol Tedeschi, Mara De Amici, Sara Manti, Valeria Brazzelli, Amelia Licari, Gian Luigi Marseglia   +11 more
wiley   +1 more source